These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26349712)

  • 1. [Cystic kidneys can now be treated].
    Schumacher B
    MMW Fortschr Med; 2015 Sep; 157(15):26. PubMed ID: 26349712
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tolvaptan and autosomal dominant polycystic kidney disease in the adult: let's give time to the "TEMPO" trial (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes)].
    Lacquaniti A
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 25083527
    [No Abstract]   [Full Text] [Related]  

  • 3. Autosomal dominant polycystic kidney disease.
    Simms RJ
    BMJ; 2016 Feb; 352():i679. PubMed ID: 26868522
    [No Abstract]   [Full Text] [Related]  

  • 4. [New strategy for the treatment of autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2015; 57(1):254-61. PubMed ID: 25735085
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease.
    Kawada T
    Clin Exp Nephrol; 2016 Feb; 20(1):147-8. PubMed ID: 26070257
    [No Abstract]   [Full Text] [Related]  

  • 7. In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease".
    Horie S; Muto S
    Clin Exp Nephrol; 2016 Feb; 20(1):149-50. PubMed ID: 26586005
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy?
    Reddy B; Chapman AB
    Am J Kidney Dis; 2015 Jun; 65(6):811-3. PubMed ID: 26003607
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolvaptan in autosomal dominant polycystic kidney disease.
    Spital A
    N Engl J Med; 2013 Mar; 368(13):1257. PubMed ID: 23534569
    [No Abstract]   [Full Text] [Related]  

  • 12. Tolvaptan in autosomal dominant polycystic kidney disease.
    Kher A
    N Engl J Med; 2013 Mar; 368(13):1257-8. PubMed ID: 23534570
    [No Abstract]   [Full Text] [Related]  

  • 13. Tolvaptan in autosomal dominant polycystic kidney disease.
    Sexton DJ
    N Engl J Med; 2013 Mar; 368(13):1258. PubMed ID: 23534571
    [No Abstract]   [Full Text] [Related]  

  • 14. Tolvaptan in autosomal dominant polycystic kidney disease.
    Jouret F; Krzesinski JM
    N Engl J Med; 2013 Mar; 368(13):1258-9. PubMed ID: 23534572
    [No Abstract]   [Full Text] [Related]  

  • 15. Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back.
    Devuyst O; Wang X; Serra A
    Nephrol Dial Transplant; 2011 Aug; 26(8):2423-5. PubMed ID: 21803730
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical experience with tolvaptan in patients with polycystic kidney disease.
    López Del Moral Cuesta C; Fernández Fresnedo G; Martín Penagos L
    Med Clin (Barc); 2020 Jul; 155(2):83-84. PubMed ID: 31130311
    [No Abstract]   [Full Text] [Related]  

  • 17. Tolvaptan in autosomal dominant polycystic kidney disease.
    Torres VE; Gansevoort RT; Czerwiec FS
    N Engl J Med; 2013 Mar; 368(13):1259. PubMed ID: 23534568
    [No Abstract]   [Full Text] [Related]  

  • 18. Aquaretic treatment in polycystic kidney disease.
    Wüthrich RP; Mei C
    N Engl J Med; 2012 Dec; 367(25):2440-2. PubMed ID: 23121376
    [No Abstract]   [Full Text] [Related]  

  • 19. Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging.
    Kistler AD; Andreisek G
    Praxis (Bern 1994); 2018 Jan; 107(3):158-164. PubMed ID: 29382260
    [No Abstract]   [Full Text] [Related]  

  • 20. V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment.
    Bennett WM
    J Am Soc Nephrol; 2005 Apr; 16(4):838-9. PubMed ID: 15728776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.